Intraoral Photobiomodulation Therapy to Prevent Oral Mucositis in Patients Undergoing Hematopoietic Cell Transplantation

Description

This is a single center pilot study evaluating intraoral photobiomodulation for the prevention of oral mucositis in patients undergoing myeloablative allogeneic hematopoietic cell transplantation (alloHCT). Patients who are planned for alloHCT will receive daily intraoral photobiomodulation therapy (PBMT) using a novel LED device. The name of the study device involved in this study is: - THOR LX2.3 with LED Lollipop

Conditions

Myeloablative Allogeneic Hematopoietic Cell Transplantation, Intraoral Photobiomodulation Therapy, Oral Mucositis, Mucosal Ulcer

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a single center pilot study evaluating intraoral photobiomodulation for the prevention of oral mucositis in patients undergoing myeloablative allogeneic hematopoietic cell transplantation (alloHCT). Patients who are planned for alloHCT will receive daily intraoral photobiomodulation therapy (PBMT) using a novel LED device. The name of the study device involved in this study is: - THOR LX2.3 with LED Lollipop

A Single Center Pilot Study of Intraoral Photobiomodulation Therapy for the Prevention of Oral Mucositis in Patients Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation

Intraoral Photobiomodulation Therapy to Prevent Oral Mucositis in Patients Undergoing Hematopoietic Cell Transplantation

Condition
Myeloablative Allogeneic Hematopoietic Cell Transplantation
Intervention / Treatment

-

Contacts and Locations

Boston

Brigham and Women's Hospital, Boston, Massachusetts, United States, 02115

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Planned to undergo myeloablative allogeneic HCT using FluBu4 conditioning and Tac-Mtx GVHD prophylaxis.
  • * Age ≥18 years.
  • * Ability to understand and the willingness to sign a written informed consent document.
  • * Participants who have had treatment with intraoral PBMT within four weeks of admission for HSCT.
  • * Participants who have a history of radiation therapy to the head and neck.
  • * Participants who have a history of photosensitivity or underlying disease with known photosensitivity.
  • * Participants who are planned to receive palifermin for OM prevention.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Dana-Farber Cancer Institute,

Kentaro Ikeda, DDS, MPH, PRINCIPAL_INVESTIGATOR, Brigham and Women's Hospital

Nathaniel S. Treister, DMD, DMSc, PRINCIPAL_INVESTIGATOR, Brigham and Women's Hospital

Study Record Dates

2025-09-19